Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2011

View Archived Issues

Novartis claims novel agents for treatment of cancer

Phase IIb immunological data disclosed on Bionor Pharma's therapeutic HIV vaccine

Novel GSK-3 inhibitor improves behavioral dysfunction in murine model of Alzheimer's disease

New cyclin-dependent kinase 9 inhibitors presented by Vichem Chemie Kutato

Kowa claims new angiotensin AT receptor antagonists/PPAR-gamma agonists

Array BioPharma patents new CSF-1-R inhibitors

GSK prepares novel antagonists of amiloride-sensitive sodium channel

Ebiotec vaccine suppresses Alzheimer's disease symptoms in vivo

Abbott updates progress of second quarter 2011

Orally active histone deacetylase inhibitor displays potent antitumor activity in vivo

Bionovo completes animal toxicology studies of Menerba

Phase II trial of PC-SOD planned in Japan and Korea

Promising new approach to treat Alzheimer's disease targets pTau

European Commission grants conditional approval to Fampyra

NanoViricides' lead anti-HIV candidate protects human CD4+ CD8+ T cells

Johnson & Johnson profiles highlights of second quarter 2011

FDA approves clinical trial of gene therapy for Wiskott-Aldrich syndrome

Vical-Astellas licensing agreements effective for TransVax

Raptor Pharmaceuticals reports phase III results on RP-103

Rib-X receives first milestone payment under Sanofi antibiotics collaboration

EMA recommends orphan drug status for 4SC's resminostat

Takeda resubmits NDAs for two diabetes therapies

Kyowa Hakko Kirin seeks Japanese approval for KW-6500

CHMP recommends new label update for GSK's Pandemrix

FDA approves new route of administration for Gammagard Liquid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...